ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
| CAPS Rating |
|
|---|---|
| Open | $8.67 |
| Previous Close | $8.68 |
| Daily Range | $8.50 - $8.67 |
| 52-Week Range | $6.25 - $9.61 |
| Market Cap | $856.09M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 230,275 |
| Average Daily Volume | 0 |
ISIS
VS S&P 500 (SPY)
How do you think ISIS will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ISIS Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ISIS News and Commentary
- The Zacks Analyst Blog Highlights: General Motors, Toyota Motor, Ford Motor, Biogen Idec and Isis Ph – NASDAQ
- Isis-Biogen Team Up - Analyst Blog – NASDAQ
- Biogen, Isis Enter Collaboration On Spinal Atrophy Treatment – SmartMoney
- Pfizer Nets Excaliard Pharma - Analyst Blog – NASDAQ
- Back to Neutral on Isis Pharma - Analyst Blog – NASDAQ
- Pfizer Signs Another Deal - Analyst Blog – NASDAQ
- Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring – The Motley Fool
- Mid-Day Update: Stocks Lower at Session's Half; Revised GDP Data Weighs on Sentiment – NASDAQ
- Pfizer Adds to Fibrosis Drug Pipeline With Excaliard Buyout – The Motley Fool
- Morning Roundup: Today's Top Stories – The Motley Fool
- Cubist Squares Well With These 2 Metrics – The Motley Fool
- Sanofi, Regeneron's Anti-Cholesterol Drug Has Good Test Results – SmartMoney
- Isis Pharmaceuticals' Shares Plunged: What You Need to Know – The Motley Fool
- The Fool Looks Ahead – The Motley Fool
- Hearty Profits: Companies Racing to Develop the Next Big Cholesterol Drug – NASDAQ
- 2 Positive Signs for Cubist Pharmaceuticals – The Motley Fool
- ISIS Pharmaceuticals' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Sanofi Sales Helped by Genzyme – Minyanville
- First in Class Isn't the Sweetest Position – The Motley Fool
- Bristol-Myers, AstraZeneca Dealt Setback on Diabetes Drug – Minyanville
RSS Headlines
Fool UK
